PharmaResearch Concludes Successful REJURAN Roadshow Across Five Western Markets

PharmaResearch Co., Ltd., a groundbreaking South Korean regenerative medicine company, has recently completed a roadshow for REJURAN, its PN-based skin booster, in five Western European markets. This initiative is part of the company's strategy to enhance its brand presence across Europe, particularly focusing on the Benelux countries, the United Kingdom, and Switzerland.

The roadshow served as an essential platform to introduce healthcare professionals to PharmaResearch's innovative DNA Optimization Technology (DOT™) and its numerous clinical applications. The events, which kicked off with a symposium in the Benelux region on April 22-23, garnered substantial interest from industry specialists who engaged actively by posing intricate questions about the product’s features and applications. The subsequent events took place in the United Kingdom on April 28 and in Switzerland on April 30. These gatherings were designed to foster networking among medical professionals from both local and regional markets.

Renowned international Key Opinion Leaders (KOLs) presented at the symposium sessions, sharing clinical results, treatment protocols, and real-world case studies while covering the entire REJURAN product lineup, including REJURAN for broader facial applications, REJURAN I for delicate areas like around the eyes, and REJURAN S for wrinkles and scars. This extensive presentation highlighted the versatility of the REJURAN portfolio, indicating its potential to fill various aesthetic needs in the growing European market.

Following positive reception from these initial presentations, PharmaResearch is expanding its European distribution network, having made its first deliveries back in January. The company’s initiative to upscale its product distribution is driven by favorable feedback from healthcare providers, prompting an increase in clinical education programs throughout the region.

Looking to the future, PharmaResearch has plans to continue its roadshow, with upcoming presentations scheduled for Italy in May, Poland in June, and France in September. The company is also eyeing an expansion into Germany and additional European markets during the latter half of the year, thereby reinforcing REJURAN’s presence across the continent.

Vera Tual, Customer Management Head at VIVACY—the European partner of PharmaResearch—commented, “Even though REJURAN is still in its early stage of introduction in Europe, there has been a palpable interest from medical professionals throughout the roadshow. Participants were eager to learn more about the product’s characteristics and practical usage, indicating that REJURAN is building momentum in Europe based on its established reputation in Asia.”

This interest reflects the healthcare community’s enthusiasm regarding REJURAN as a new PN product for aesthetic practices in Europe. VIVACY is also keen to leverage this partnership to connect with a broader network of medical professionals throughout Europe.

A representative from PharmaResearch stated, “The demand for PN-based injectable products is growing in Europe, yet the market remains in its early developmental phase. We believe the time is right to introduce REJURAN as a trusted PN-based skin booster, supported by our DOT™ technology and extensive clinical experience.” He further elaborated that the momentum for REJURAN in Europe is advancing quicker than anticipated, which can be attributed to its existing global presence in other markets along with the strength of the DOT™ technology and the relevance of its product lineup for healthcare professionals. Due to the encouraging feedback, PharmaResearch has raised its internal targets and is committed to expanding its sales and educational programs across Europe.

Company Background: PharmaResearch is a pioneering biopharmaceutical firm dedicated to improving people’s quality of life through regenerative medicine. Its diverse portfolio includes pharmaceuticals, medical devices, cosmetics, and dietary supplements, all centered around the patented core ingredients DOT™ PDRN and DOT™ PN. Headquartered in Gangneung-si, Gangwon-do, South Korea, the firm also has a subsidiary in Costa Mesa, California, USA.

For further information, visit PharmaResearch.

About Laboratoires VIVACY: Established in 2007, Laboratoires VIVACY is a French manufacturer of high-quality medical products based on hyaluronic acid, headquartered in Paris. Recognized for its proprietary IPN-Like Technology, VIVACY is well-known for STYLAGE® dermal fillers and DESIRIAL®, the world’s first injectable product for functional and aesthetic gynecology. Recently, VIVACY has entered strategic partnerships with Burgeon Biotechnology for the CaHA biostimulator NOVUMA® and PharmaResearch for the exclusive European distribution of REJURAN® skin boosters. With products manufactured in its state-of-the-art facility at Archamps Technopole, France, VIVACY has a presence in over 85 countries. For more details, visit VIVACY.